BioSpace News Archive

Invitae (NYSE: NVTA), a leading medical genetics company, today announced three studies demonstrating the benefits of genetic testing for all breast cancer patients, impacting treatment decisions and cancer screening for patients and their families

Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the progression of REDWOOD-HCM following the conduct of an interim analysis of data from Cohort 1. REDWOOD-HCM ( R andomized E valuation of D osing W ith CK-274 in O bstructive O utflow D isease in HCM ) is an ongoing Phase 2 clinical trial of CK-3773274 (CK-274), a next-generation cardiac myosin inhibitor in development for the potential treatment of hypertrophic car

PepGen’s proprietary cell-penetrating peptide technology promises enhanced safety, efficacy, and improved delivery to cardiac muscle; Oxford Sciences Innovation, The University of Oxford, and CureDuchenne Ventures also participated in the Series A round

9 Meters Biopharma, Inc., a clinical-stage rare and unmet needs-focused gastroenterology company, announced that the United States Food and Drug Administration has granted orphan drug designation to NM-003, a proprietary long-acting GLP-2 receptor agonist, for prevention of acute graft versus host disease.

Protech Home Medical Corp. a U.S. based leader in the home medical equipment industry, focused on end-to-end respiratory care, announced that Dr. Kevin A. Carter has joined the board of directors of the Company as an independent director.

Presentations highlight lumateperone ’s broad antidepressant effects in patients with bipolar disorder and in patients with schizophrenia with co-morbid depression NEW YORK, Dec. 09, 2020 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced two presentations at the 59th Annual Meeting of the American College of

Whole antibodies have grabbed a significant share of the global sales revenue as well as the volume of the biopharmaceuticals market.

Hair transplantation is the most widely performed esthetic surgical procedure. It is the only alternative method to recover hair loss in some hair diseases such as genetic hair loss or cicatricle alopecia.

Hyaluronidase are enzymes that catalyze the degradation of hyaluronic acid. These enzymes are widely employed in esthetic medicine.

Tissue plasminogen activator (tPA) is an enzyme associated with breakdown of blood clots (fibrinolysis).